Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab.
Anticancer Res
; 40(7): 4047-4051, 2020 Jul.
Article
en En
| MEDLINE
| ID: mdl-32620651
ABSTRACT
BACKGROUND/AIM:
Infusion reactions (IRs) often occur with trastuzumab. Although premedication by non-steroidal anti-inflammatory drugs can be effective to a certain extent, IRs are still common and infrequently severe. Therefore, a predictive marker that can select patients requiring further prophylaxis is useful for appropriate prevention, but remains unclear. PATIENTS ANDMETHODS:
We conducted a retrospective analysis for 136 consecutive female inpatients aged 18 years and older who received 8 mg/kg of the initial trastuzumab administration for breast cancer with a 25-mg dose of rectal diclofenac before trastuzumab infusion between May 2007 and April 2019, in order to assess IRs.RESULTS:
Overall, 57 patients were eligible for inclusion in the study. IRs were observed in 17.5% (10/57) of the patients. Univariate analysis showed that patients with a low eosinophil percentage (≤2%) were associated with IRs (p=0.016).CONCLUSION:
A low eosinophil percentage can be a useful new predictive marker for trastuzumab-induced IRs in patients with breast cancer.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Eosinófilos
/
Trastuzumab
/
Reacción en el Punto de Inyección
/
Antineoplásicos Inmunológicos
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Anticancer Res
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón